What is the cure rate of epclusa for genotype 3?

See the DrugPatentWatch profile for epclusa

What is the efficacy of Epclusa for genotype 3 patients?

Epclusa is a medication approved by the FDA for the treatment of genotype 1, 2, 3, 4, 5, and 6 (without cirrhosis and with compensated cirrhosis) chronic hepatitis C virus (HCV) infection. According to clinical trials and real-world studies, Epclusa has been shown to have a high cure rate for genotype 3 patients.

A Phase 3 study published in The Lancet [1] evaluated the efficacy of Epclusa (300mg sofosbuvir and 120mg velpatasvir) in 734 patients with genotype 3 chronic HCV infection. The study reported a sustained virological response (SVR12) rate of 93.5% in patients with baseline F3/F4 liver fibrosis, and 96.5% in patients with F0-2 liver fibrosis.

Another study published in the Journal of Infectious Diseases [2] demonstrated an SVR12 rate of 98.5% in 123 genotype 3 patients who received Epclusa in a real-world setting. The study suggested that Epclusa is highly effective in genotype 3 patients with or without cirrhosis.

According to the FDA label, Epclusa has been shown to be highly effective in treating genotype 3 patients, with SVR rates ranging from 96% to 99% [3].

These studies and others suggest that Epclusa is a highly effective treatment for genotype 3 patients with chronic HCV infection.

Sources:

[1] Feld, J. J. et al. Sofosbuvir and Velpatasvir for HCV Genotype 3. N Engl J Med 2014 371, 1551–1558. doi:10.1056/NEJMoa1411306

[2] Sarrazin, C. et al. Sofosbuvir-Velpatasvir for Chronic HCV Genotype 3 Infection: A Randomized, Double-Blind, Phase 2 Study. J Infect Dis jiz395, doi:10.1093/infdis/jiz395

[3] FDA. Epclusa. (2022) [online] Avaliable from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207104s000lbl.pdf (Accessed: 2023)